Information Provided By: 
Fly News Breaks for August 29, 2017
IMGN, JAZZ
Aug 29, 2017 | 14:45 EDT
Wells Fargo analyst David Maris said Jazz Pharmaceuticals' (JAZZ) collaboration and option agreement on two early-stage, hematology-related antibody-drug conjugate programs with ImmunoGen (IMGN) is a sensible one for Jazz that strategically fits well with existing products and he expects Jazz investors will like the deal. However, he also thinks "many are waiting for a larger deal" to diversify Jazz's current revenue base. Maris keeps an Outperform rating on Jazz shares.
News For JAZZ;IMGN From the Last 2 Days
There are no results for your query JAZZ;IMGN
